Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb;191(1):53-9.
doi: 10.1007/s00408-012-9436-2. Epub 2012 Nov 13.

Diffuse alveolar hemorrhage in coumarin users: a fibrosing interstitial pneumonia trigger?

Affiliations

Diffuse alveolar hemorrhage in coumarin users: a fibrosing interstitial pneumonia trigger?

Petal A Wijnen et al. Lung. 2013 Feb.

Abstract

Background: Fibrosing interstitial pneumonias (IPs) include idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP). It has been suggested that oxidative damage plays a role in the pathophysiology of idiopathic interstitial pneumonias. Diffuse alveolar hemorrhage (DAH) can cause oxidative stress. Accordingly, we hypothesized that episodes of DAH might trigger fibrosing IP development.

Methods: Patients using coumarins with confirmed DAH were retrospectively gathered during a 9 year period and reviewed for the development of IPF or fibrosing NSIP.

Results: A total of 65 patients with DAH could finally be included, 31 (48 %) of whom subsequently developed a fibrosing IP. The majority of these 31 patients developed the fibrosing IP within 3 years after DAH confirmation. A total of 41 (63 %) patients died within 3.0 ± 0.9 (range 1.3-4.7) years after the DAH diagnosis had been confirmed. Twenty-two of the deceased (54 %) had finally developed fibrosing IP.

Conclusions: Almost half of the patients with established episodes of DAH developed fibrosing IP; therefore it seems that DAH might be a trigger for the development of fibrosing IP. This observation warrants prospective studies to further evaluate the clinical impact of these findings.

PubMed Disclaimer

References

    1. Eur Respir J. 2006 Jan;27(1):143-50 - PubMed
    1. Respiration. 1998;65(6):486-8 - PubMed
    1. Biochem Biophys Res Commun. 1985 Apr 16;128(1):211-9 - PubMed
    1. Am J Surg Pathol. 2007 Feb;31(2):277-84 - PubMed
    1. Am J Hematol. 2007 Jul;82(7):656-60 - PubMed

MeSH terms

LinkOut - more resources